Eric Percher

I'd like to get a little bit more on Navista and ION and the impairment

Can you give us a bit more on capital allocation and maybe also the capacity or opportunity for further transactions

help us understand maybe some of the cadence you saw in Q1, that pull-through and then expectation for the remainder of the year

So I'd be interested to hear what they may be adding in terms of capabilities or opportunities versus what you're adding. And then, Aaron, what I'd ask you, I know we don't have accretion beyond th...

how does the action to offset for Cardinal brand differ from national brand? And is there a general expectation of ability to pass

Can you tell us is the Cardinal brand still growing? Has there been any change in trajectory

can we check that assumption? And then, relative to GL1 -- GLP-1 inventory, have you been able to optimize as growth stabilizes

when you sit across from a manufacturer and you have a discussion whether it has been AMP or where we are this year with the price reductions

can you remind us maybe how the OneOnco acquisition contribution flows in at the segment level versus what you gave us at total company being neutral

your perspective on what is enabling the pivot to 5% to 8% growth in '26 and enables the long-term guide at that level

you've had 3 months to process the full spectrum of potential policies. Any thoughts on potential impact across brand versus generic

can you help us with your view of the profit stream? And we've talked a lot about the opportunity

I'd be interested in your perspectives on the challenges we've seen in practice management 20 years ago and physician enablement more recently

are you seeing an uptick in Q3 versus first half where you're serving specialty pharmacies

clarify the extent to which you're seeing pressure from adoption of TrueCost versus change in mix

It's proven harder to draw a line in the sand on delivery HBR. Can you speak to visibility at this point of the year

it feels like the distributor value prop has held up very strong in the face of IRA

There are several macro indicators of specialty volume treatment acuity that have expanded the last 2 quarters

Is this now a segment where we should look at the full year guidance and expect that it's really going to be difficult

I'm curious to hear if the step-up in guidance reflects that you believe the macro environment stays that strong

How much of that do you attribute to the macro trends versus what is unique about your specialty business